With years of research and teaching experience, including a former position as chief of cardiology of the Yale School of Medicine, Dr. Michael Simons serves as the Yale-University-College London (UCL) Biomedicine Consortium’s co-director. Created by Dr. Michael Simons in collaboration with a UCL professor, the concept initially took root as a cardiovascular program and ultimately grew into a pan-medical school and pan-university program.
Dr. Simons’ earned his MD cum laude at the Yale University School of Medicine and undertook a postdoctoral fellowship at the National Institutes of Health’s Laboratory of Molecular Cardiology. He subsequently pursued a cardiology fellowship at Beth Israel Hospital in Boston, Massachusetts, and was an associate scientist with the Massachusetts Institute of Technology’s Program for Excellence in Molecular Biology of the Cardiovascular System.
Dr. Simons has guided groundbreaking research in areas such as syndecan-4 signaling, as well as VEGF signaling and vascular homeostasis regulation. His laboratory recently advanced understanding of the disease process in atherosclerosis, which underlies strokes and heart attacks. The findings were presented at the 2015 North American Vascular Biology Organization’s Cardiovascular Signaling workshop.
